HER2 Support Group Forums - View Single Post - Ki67 Level 2 Weeks After Starting Arimidex Predicts Breast Cancer Relapse

R.B. · 06-25-2006, 04:17 PM

Not BC but interesting re potential communality of mechanism.

And links to FAS.

HER2 links to FAS.

Herceptin blocks FAS as one of its mechanisms per reports.

RB

http://www.ncbi.nlm.nih.gov/entrez/q...=pubmed_DocSum

1: Oral Oncol. 2004 Aug;40(7):688-96. Related Articles, Links
Click here to read
Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study.

Silva SD, Agostini M, Nishimoto IN, Coletta RD, Alves FA, Lopes MA, Kowalski LP, Graner E.

Department of Oral Diagnosis, School of Dentistry of Piracicaba, UNICAMP, Av. Limeira 901, CP52, Areao, 13414-018, Brazil.

Fatty acid synthase (FAS) is a multifunctional enzyme responsible for the synthesis of saturated fatty acids using acetyl-CoA and malonyl-CoA as substrates. Overexpression of FAS has been reported in several human malignancies and suggested as a potential prognostic factor. ErbB2 (Her-2/neu), a transmembrane tyrosine kinase member of the ErbB receptor family, is known to be overexpressed in a variety of tumors and was recently shown to regulate FAS production in breast epithelial cell lines. Herein we analyzed by immunohistochemistry the expression of FAS, ErbB2, and the proliferation marker Ki-67 in 62 head and neck squamous cell carcinoma (HNSCC) samples. Approximately 78% of the cases were positive for FAS or ErbB2 at the cell membrane and 70% of the tumors that showed a high expression of FAS were also strongly positive for ErbB2 (Fisher's exact test, p = 0.01). The immunolabeling for both FAS and ErbB2 was stronger in histologically well-differentiated lesions. Additionally, Ki-67 expression was significantly associated with a poor prognosis (log-rank test, p = 0.03). Taken together, the results presented here suggest that ErbB2 regulates FAS expression in HNSCC and point out Ki-67 as a useful prognostic marker for these tumors.

PMID: 15172638 [PubMed - indexed for MEDLINE]

06-25-2006, 04:17 PM	#4
R.B. Senior Member Join Date: Mar 2006 Posts: 1,843	More linking Ki 67, HER2, FAS Not BC but interesting re potential communality of mechanism. And links to FAS. HER2 links to FAS. Herceptin blocks FAS as one of its mechanisms per reports. RB http://www.ncbi.nlm.nih.gov/entrez/q...=pubmed_DocSum 1: Oral Oncol. 2004 Aug;40(7):688-96. Related Articles, Links Click here to read Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study. Silva SD, Agostini M, Nishimoto IN, Coletta RD, Alves FA, Lopes MA, Kowalski LP, Graner E. Department of Oral Diagnosis, School of Dentistry of Piracicaba, UNICAMP, Av. Limeira 901, CP52, Areao, 13414-018, Brazil. Fatty acid synthase (FAS) is a multifunctional enzyme responsible for the synthesis of saturated fatty acids using acetyl-CoA and malonyl-CoA as substrates. Overexpression of FAS has been reported in several human malignancies and suggested as a potential prognostic factor. ErbB2 (Her-2/neu), a transmembrane tyrosine kinase member of the ErbB receptor family, is known to be overexpressed in a variety of tumors and was recently shown to regulate FAS production in breast epithelial cell lines. Herein we analyzed by immunohistochemistry the expression of FAS, ErbB2, and the proliferation marker Ki-67 in 62 head and neck squamous cell carcinoma (HNSCC) samples. Approximately 78% of the cases were positive for FAS or ErbB2 at the cell membrane and 70% of the tumors that showed a high expression of FAS were also strongly positive for ErbB2 (Fisher's exact test, p = 0.01). The immunolabeling for both FAS and ErbB2 was stronger in histologically well-differentiated lesions. Additionally, Ki-67 expression was significantly associated with a poor prognosis (log-rank test, p = 0.03). Taken together, the results presented here suggest that ErbB2 regulates FAS expression in HNSCC and point out Ki-67 as a useful prognostic marker for these tumors. PMID: 15172638 [PubMed - indexed for MEDLINE]